EXHIBIT 10.1

SEPARATION AGREEMENT

THIS AGREEMENT dated as of March 16, 2023 (“Agreement”) is made by and between Zomedica Corp. (the “Company”) and Ann Marie Cotter (“Executive”).

WHEREAS, Executive is employed as the Chief Financial Officer of the Company and the Company’s wholly owned subsidiary, Zomedica Inc., and

WHEREAS, the parties wish to enter into this Agreement regarding their separation, subject to the execution of the Consulting Agreement of even date (the “Consulting Agreement”).

ACCORDINGLY, in consideration of the execution and delivery of this Agreement and the compliance with the promises made herein, the parties agree that the precatory clauses above are incorporated herein and further agree as follows:

1. Last Day of Employment. Executive’s last day of employment as Chief Financial Officer is March 16, 2023 and her last date of employment with the Company is April 15, 2023 (the “Separation Date”).

2. Separation Benefits. In exchange for the mutual promises made in the Agreement, the parties shall do the following:

(a) The Company shall compensate Executive through the Separation Date in accordance with normal payroll practices, provided that Employee performs transition services reasonably requested by Company through the Separation Date.

(b) The Company shall reimburse Executive for business expenses incurred through the Separation Date in accordance with the Company’s policies and procedures.

(c) The Company shall pay Executive the prorated portion of her annual cash bonus based on thirty-five percent (35%) of base salary subject to applicable withholdings and payable no later than thirty (30) days following the Separation Date.

(d) The Company shall pay Executive for any accrued but unused paid time-off at the time of the next regular payroll payment following the Separation Date subject to applicable local, state, federal and social security tax withholdings.

(e) The Company shall pay Executive an amount equal to twelve (12) months of her three hundred thousand dollar ($300,000) base annual salary to be paid in accordance with normal payroll procedures for three (3) months following the Separation Date and the balance to be paid in a lump sum within ninety (90) days of the Separation Date subject to applicable local, state, federal and social security tax withholdings.

(f) The Company and Executive agree to jointly draft a press release on her transition, characterizing it in positive terms.

(g) Executive shall transition to a consulting role according to the terms of the Consulting Agreement.

(h) Notwithstanding any provisions concerning stock vesting which may be to the contrary, the Company agrees that those certain stock options granted pursuant to an Option Agreement dated March 13, 2020 and an expiration of March 12, 2025, an Option Agreement dated October 1, 2020 and an expiration of September 30, 2025, and an Option Agreement dated December 31, 2020 with an expiration of December 30, 2030 shall become immediately vested as of the Separation Date and shall be exercisable in accordance with the terms of the Company’s Option Plan.

3. Confidentiality. Executive is subject to obligations of confidentiality pursuant to her Work Agreement dated August 27, 2018. Such obligations survive Executive’s separation from service in accordance with the terms of such Work Agreement.

In addition, notwithstanding this provision or any other provision of this Agreement, Executive and the Company agree that Executive, pursuant to the Defend Trade Secrets Act of 2016, shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (ii) is made solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition and without limiting the preceding sentence, if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney and may use the trade secret information in the court proceeding, if Executive: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

4. Confidentiality of Agreement. The parties represent and agree that they will keep the negotiations surrounding this Agreement confidential, and that they will not hereafter disclose (except as required by law) any information concerning the negotiations of this Agreement to any person other than their attorneys and financial or tax advisors or, in the case of the Executive, Executive’s immediate family, provided each is informed of and agrees in advance to be bound by this confidentiality provision; provided further that all parties acknowledge and agree that if applicable law requires the filing of this Agreement with the Securities and Exchange Commission (“SEC”), then no confidentiality obligation is imposed relating to any information the Company files with the SEC. Nothing in this Agreement prevents or precludes Executive from cooperating with any inquiry by the SEC or any other regulatory agency or body.

5. Survival of Company Indemnification Obligations. All obligations of the Company to indemnify and defend Executive, and advance fees, costs and expenses to Executive, in each case pursuant to the Indemnity Agreement dated December 28, 2022, shall survive the Executive’s separation from service in accordance with the terms of such Indemnity Agreement. The Company shall not take any action that would terminate or limit the Company’s obligations to indemnify Executive, including without limitation by amending its bylaws.

6. Mutual Release and Waiver.

(a) Executive forever releases and discharges the Company, its parent, owners, agents, directors, officers, employees, and affiliates, of and from any and all claims, demands, equitable relief, damages, costs, expenses, administrative actions and causes of action of any kind or character, whether known or unknown, including, but not limited to, those claims relating in any manner to or arising from Executive’s employment with the Company, or the separation thereof, or which may otherwise arise under any federal or state statute, the common law or in equity, including but not limited to any claim arising under the Americans with Disabilities Act, the Age Discrimination in Employment Act ("ADEA"), the Employee Retirement Income Security Act, the Family and Medical Leave Act, the Fair Labor Standards Act, Title VII of the Civil Rights Act of 1964, the Michigan Elliott-Larsen Civil Rights Act, or the Michigan Persons With Disabilities Civil Rights Act, all as amended, and contract or tort claims, provided that, nothing in this provision or Agreement shall preclude Executive from seeking a judicial determination regarding the validity of this waiver with respect to any claims under the ADEA..

(b) The Company forever releases and discharges Executive from any claims, actions, causes of action, suits, debts, charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, and expenses in law or in equity, arising from or relating to Executive's employment with the Company, with the exception of claims related to fraud or embezzlement.

7. Non-Admission of Liability. This Agreement shall not be construed as an admission, nor is it an admission, by either party that it is liable in any respect for any claim or cause of action that has been or may hereafter be asserted. This Agreement is being entered into solely for the purpose of conferring consideration upon both parties in return for their resolution of the matters enumerated above.

8. Conditions of Effectiveness of this Agreement.

(a) Right to Review Agreement. Executive acknowledges and agrees that Executive has been offered a period of up to twenty-one days to review this Agreement with any attorneys, financial advisors or immediate family members, that Executive has been advised by the Company to do so, and to the extent Executive desires, has done so, that Executive has used the full twenty-one day period for such review or has voluntarily chosen to execute this Agreement before the end thereof, that Executive has read and understood the release provided herein and that Executive has knowingly and voluntarily agreed to all the terms of this Agreement and that Executive has signed this Agreement voluntarily without any coercion.

(b) Revocation. Executive has seven (7) days following the date upon which Executive signs and delivers this Agreement to the Company to revoke acceptance of the Agreement, except that the revocation shall be effective only if it is made in writing addressed to the Company and includes the statement: “I hereby revoke my acceptance of our Agreement,” and such written revocation is delivered to the Company by hand, registered mail, certified mail (return receipt requested) or overnight mail at 100 Phoenix Drive, Suite 190, Ann Arbor, Michigan 48108, Attn: Larry Heaton.

9. Non-disparagement. The parties agree not to make or publish any statement or take any action intended to defame, disparage, humiliate, embarrass, or discredit each other or any of the other applicable Releases, their management, or their practices. Executive further agrees not to take any action that would disrupt or impair the Company’s operations; provided, that this provision shall not limit or prohibit a party from taking any action required by this Agreement or the Consulting Agreement or to enforce the terms of this Agreement or the Consulting Agreement.

10. Reasons for Separation. The parties agree that they will in all public statements refer to the Executive’s separation and the reasons therefor in a manner consistent with the press release issued in connection such termination.

11. Governing Law and Interpretation; Venue. This Agreement shall be governed by the laws of the State of Michigan without regard to its conflict-of-laws principles. Any and all disputes relating to or arising out of this Agreement, Executive’s employment with the Company or the termination of that employment shall be brought solely and exclusively in the federal or state courts located in Michigan.

12. No Actions. Each party represents that it has not commenced, maintained, prosecuted or participated in any action, charge, complaint or proceeding of any kind (on his/its own behalf and/or on behalf of any other person and/or on behalf of or as a member of any alleged class of persons) that is pending in any court, or before any administrative or investigative body or agency (whether public, quasi-public, or private) against or involving the other party or any of his/its affiliates, including for the Company Zomedica, Inc. Each party represents that it is not aware of or participating in any effort by any person or entity to assert any action, charge, complaint or proceeding of any kind, whether in court or before an administrative body or agency (whether public, quasi-public, or private), against or involving the other party or any of his/its affiliates, including for the Company Zomedica, Inc.

13. Entire Agreement: Amendment. This Agreement contains the entire understanding of the parties and supersedes all previous verbal and written agreements concerning the same subject matter, except as expressly referred to or set forth herein. This Agreement may only be modified in writing signed by both parties.

14. Return of Company Property. Executive agrees to return, upon the Company's request, any Company property in her control or in her possession.

15. Negotiated Agreement. This Agreement amicably resolves any issues between the parties, and they agree that this Agreement and its accompanying exhibit agreements shall neither be interpreted nor construed as an admission of any wrongdoing or liability on the part of the Company or the Executive and that neither party shall be considered the primary drafter of this Agreement or its accompanying exhibit agreements.

16. Acknowledgement. The parties hereby acknowledge that they have read this Agreement, have had an adequate opportunity to review its terns and have been advised to consult with legal counsel before signing this Agreement. They further acknowledge that they understand this Agreement's terms and consequences and are executing it freely and voluntarily.

17. Binding. This Agreement shall be binding upon and inure to the benefit of Executive and the Company, and their respective heirs, administrators, successors and assigns.

18. Counterparts; Facsimile and Electronic Signatures. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument. Facsimile and electronic counterpart signatures on this Agreement shall be valid and binding.

NOW, THEREFORE, the Company and Executive now knowingly and voluntarily sign this Agreement on the date set forth below.

EXHIBIT 10.2

March 14, 2023

Peter Donato

[REDACTED]

Dear Peter:

On behalf of Zomedica Inc., I am pleased to extend an offer of employment to you for the position of Chief Financial Officer, reporting to me.

Start Date. Your proposed start date is March 16, 2023, or an earlier date mutually agreed upon.

Base Salary. Your bi-weekly salary will be $12,500.00 (equivalent to $325,000 per year). You will be eligible for annual performance-based increases in salary.

Bonus. You will be eligible for a bonus equal to 40% of your base salary, dependent on established company and individual goals and objectives. For 2023, you will be eligible for a full year payout (not pro-rated).

Relocation Bonus. Upon the completion of your relocation to Michigan, you will receive a one-time bonus in the amount of $35,000, subject to applicable tax withholding. This relocation bonus offer expires on 3/1/2024, and if earned, will be paid no later than March 15, 2024.

Commuting Expenses. The Company will reimburse you up to $3,000 per month for commuting expenses, upon submittal of receipts through the Company’s normal expense reimbursement process, until the completion of relocation or 3/31/2024, whichever comes first. Reimbursement will in all events be paid within 30 days of the date the request for expense reimbursement is submitted and not later than March 15 of the year after the year the relevant expense is incurred.

Equity Position. You will be awarded an initial option to purchase 5,000,000 shares of Zomedica common stock at a strike price equal to the closing price of our stock on the later of the trading day of the formal approval of your options at a regularly scheduled meeting of the Zomedica Board of Directors or your employment date. You are eligible for an additional grant of options on your one year anniversary.

Your options will be subject to our Option Plan and our standard form option agreement which includes a four-year vesting schedule (with 25% vesting annually) for each issuance of options.

Benefit Plans. You will be eligible for all Zomedica benefit plans offered to Zomedica employees according to the terms of those plans, effective the first of the month following date of hire. This includes medical insurance, a 401(k) plan, and employer-paid vision, dental, short-term disability, long-term disability, and life insurance.

PTO. In addition to Zomedica’s ten paid holidays and two floating holidays in a full calendar year, you will enjoy three weeks of PTO annually. Accrual of PTO begins on your first day of employment.

Change of Control. In the event that Zomedica experiences a “change of control”, and you are separated from Zomedica as a result, you will be provided a severance payment to include one year’s salary and a payment equal to one year’s COBRA payments. Severance will be paid in a lump sum on the Company’s first ordinary payroll date following your “separation from service” (within the meaning of Section 409A of the Internal Revenue Code), subject to any delay required under Treasury Regulation Section 1.409A-3(i)(2). For purposes of this letter, a “change of control” shall mean a “change of control of the Corporation” as defined in Zomedica’s Amended and Restated Stock Option Plan (as in effect on the date hereof and filed with the U.S. Securities and Exchange Commission).

This offer of employment is not intended to, nor does it, constitute a contract of employment. Your employment with Zomedica Inc. will be on an at-will basis, consistent with applicable law. This offer is subject to the successful completion of background checks, and signature to a confidentiality, non-compete, and non-solicitation agreement.

With a lot of exciting work ahead of us, we’re confident that you will be a key addition to both the Company and our leadership team and look forward to having you join and share in our success.

Please indicate your acceptance of this offer by signing this letter and returning it to me on or before March 15, 2023, at which time it will expire unless fully executed.

Sincerely,

Larry Heaton

CEO

Acceptance:

My signature below indicates I fully agree to the terms of the employment offer designated above.